BioCentury | Sep 24, 2012
Finance

Hopp stays the course

...receiving dividends from two profitable drug delivery companies in its portfolio: Cosmo Pharmaceuticals S.p.A. and LTS Lohmann Therapie-Systeme AG...
...Madrid, Spain immatics biotechnologies GmbH , Tuebingen, Germany Integrated Diagnostics Inc. , Seattle, Wash. LTS Lohmann Therapie-Systeme AG...
...Germany Medical devices 2004 50% 90% Developing minimally invasive endoscopic spine surgery products and techniques LTS Lohmann Therapie-Systeme AG...
BioCentury | Sep 2, 1997
Clinical News

NicErase-SL lobeline sulfate sublingual tablets data

DYGN announced that its 750-patient, Phase III trial failed to demonstrate a statistically significant difference between NicErase-SL tablets and placebo. Based on the results, DYGN will discontinue its NicErase-SL program. DYGN has licensed NicErase to...
BioCentury | Jun 2, 1997
Company News

DynaGen, LTS Lohmann Therapie Systeme GmbH, Nastech deal

DYGN and LTS signed a memorandum of understanding for evaluation and possible development of DYGN's NicErase transdermal and buccal formulations for smoking cessation therapy. DYGN will license the NicErase technology, expertise and patents to LTS,...
BioCentury | Jan 30, 1995
Company News

Alza news

AZA (Palo Alto) and Marion Merrell Dow Inc. (Kansas City, Mo.) sued Ciba-Geigy Corp. and LTS Lohmann Therapy Systems Corp., alleging infringement of two U.S. Patents issued to AZA - Nos. 5,344,656 and 5,364,630 - which relate...
Items per page:
1 - 4 of 4
BioCentury | Sep 24, 2012
Finance

Hopp stays the course

...receiving dividends from two profitable drug delivery companies in its portfolio: Cosmo Pharmaceuticals S.p.A. and LTS Lohmann Therapie-Systeme AG...
...Madrid, Spain immatics biotechnologies GmbH , Tuebingen, Germany Integrated Diagnostics Inc. , Seattle, Wash. LTS Lohmann Therapie-Systeme AG...
...Germany Medical devices 2004 50% 90% Developing minimally invasive endoscopic spine surgery products and techniques LTS Lohmann Therapie-Systeme AG...
BioCentury | Sep 2, 1997
Clinical News

NicErase-SL lobeline sulfate sublingual tablets data

DYGN announced that its 750-patient, Phase III trial failed to demonstrate a statistically significant difference between NicErase-SL tablets and placebo. Based on the results, DYGN will discontinue its NicErase-SL program. DYGN has licensed NicErase to...
BioCentury | Jun 2, 1997
Company News

DynaGen, LTS Lohmann Therapie Systeme GmbH, Nastech deal

DYGN and LTS signed a memorandum of understanding for evaluation and possible development of DYGN's NicErase transdermal and buccal formulations for smoking cessation therapy. DYGN will license the NicErase technology, expertise and patents to LTS,...
BioCentury | Jan 30, 1995
Company News

Alza news

AZA (Palo Alto) and Marion Merrell Dow Inc. (Kansas City, Mo.) sued Ciba-Geigy Corp. and LTS Lohmann Therapy Systems Corp., alleging infringement of two U.S. Patents issued to AZA - Nos. 5,344,656 and 5,364,630 - which relate...
Items per page:
1 - 4 of 4